Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 153 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lopinavir / Ritonavir Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

NCT00135434
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir/Ritonavir/Lopinavir/ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 2Phase 3 Interventional

Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor

NCT00038519
View directory record Official record
Conditions
HIV Infections
Interventions
Amprenavir/ritonavir, Saquinavir/ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2006 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 3 Interventional

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

NCT00050895
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Efavirenz, Stavudine, Zidovudine, Lamivudine, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
59
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Post-Exposure Prophylaxis in Health Care Workers

NCT01234116
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
emtricitabine/tenofovir disoproxil fumarate
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

NCT00711009
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection
Interventions
lopinavir/ritonavir (LPV/r), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), raltegravir (RAL)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • Atlantis, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 24, 2026, 9:35 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

NCT01923311
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
EVG, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 2 Interventional

A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

NCT00075231
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra® (lopinavir/ritonavir), Combivir® (lamivudine, zidovudine), Sustiva® (efavirenz)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2006 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 4 Interventional Results available

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV

NCT00244712
View directory record Official record
Conditions
HIV Infection
Interventions
emtricitabine/tenofovir, abacavir/lamivudine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Sep 24, 2026, 9:35 PM EDT
Withdrawn Not applicable Interventional

Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis

NCT00023218
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Lopinavir/Ritonavir, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Honolulu, Hawaii • Tripler AMC, Hawaii • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 2 Interventional

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

NCT00046033
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Amprenavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Miami, Florida • Honolulu, Hawaii • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Not applicable Interventional Results available

Comparison of Liquid Kaletra and Low Dose Kaletra Tablets

NCT00762320
View directory record Official record
Conditions
HIV Infections
Interventions
Low dose Kaletra tablets
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
3 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 23, 2014 · Synced Sep 24, 2026, 9:35 PM EDT
Terminated Phase 2 Interventional Results available

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

NCT00090779
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Torrance, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole

NCT01660477
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Lopinavir/Ritonavir, Healthy Volunteers
Interventions
Isavuconazole, Lopinavir/ritonavir
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 2 Interventional Results available

Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

NCT00949234
View directory record Official record
Conditions
HIV Prevention, HIV Infections
Interventions
tenofovir + emtricitabine, lopinavir/ritonavir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

LAAM-HAART PET Imaging

NCT01935830
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[11c] LAAM, Ritonavir, Efavirenz
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 3 Interventional

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

NCT00004583
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Nelfinavir mesylate, Lamivudine, Stavudine
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
42
States / cities
Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 2 Interventional

Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients

NCT00116636
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra
Drug
Lead sponsor
Therapeutic Concepts
Other
Eligibility
18 Years and older
Enrollment
40 participants
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Not applicable Interventional

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

NCT00028314
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Wasting Disease
Interventions
Abacavir sulfate, Atazanavir/Ritonavir, Lopinavir/Ritonavir, Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
25
States / cities
Los Angeles, California • Torrance, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Sep 24, 2026, 9:35 PM EDT
Recruiting Phase 1 Interventional

Lopinavir/Ritonavir in PLWH With High-Grade AIN

NCT05334004
View directory record Official record
Conditions
High-Grade Anal Intraepithelial Neoplasia
Interventions
Lopinavir / Ritonavir
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 2 Interventional Results available

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

NCT00654147
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir & Lopinavir/ritonavir, Raltegravir and emtricitabine/tenofovir
Drug
Lead sponsor
Margaret A. Fischl, M.D.
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 2 Interventional

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

NCT00036452
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, emtricitabine, stavudine, tenofovir DF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
27
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 3 Interventional

A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment

NCT00004581
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Nevirapine
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Sep 24, 2026, 9:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First in Human Study of TLC-ART 101 (ACTU 2001)

NCT05850728
View directory record Official record
Conditions
Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
Interventions
TLC-ART
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 24, 2026, 9:35 PM EDT